nucleoside complexes (1-4) did not show appreciable cytotoxicity, the corresponding amidine derivatives (7a, 7b, 8a, 8b, 5b, and 6b) exhibited a significant in vitro antitumor activity.
Introduction
The coordination chemistry of DNA components to metal centers has been thoroughly characterized [1] [2] [3] . In particular, after the discovery of biological activity of cis-Pt(NH 3 ) 2 Cl 2 [4] [5] [6] , the interactions of platinum (II and IV) [7] [8] [9] [10] complexes with model nucleobases, nucleosides and nucleotides, have been studied in great detail [11] [12] [13] [14] [15] [16] [17] . In this field we have shown that the neutral ligands in the cisplatin analogs cis-Pt (PR 3 ) 2 Cl 2 (PR 3 = phosphines and diphosphines) play an important role in the nuclearity and reactivity of the platinum-nucleobase adducts. As an example, the reaction of the hydroxo complex cis-[L 2 Pt(μ-OH)] 2 (NO 3 [19] . In addition, the trinuclear species is stable in solution of nitriles (MeCN, PhCN), whereas the mononuclear species reacts with the solvent to give the amidine derivatives cis-[(PPh 3 ) 2 PtNH=C(R){1-MeCy(−2H)}]NO 3 (R=Me, Ph) [20, 21] .
We have now extended these studies on the reactivity of cis-[L 2 Pt (μ-OH)] 2 (NO 3 ) 2 (L = PMe 3 , PPh 3 ) to the nucleosides cytidine (cyt) and adenosine (ado), shown in Scheme 1.
In this paper we report the synthesis and characterization of new nucleoside complexes along with an investigation on their cytotoxic properties against a panel of human cancer cell lines. The high antitumor activity exhibited by the species cis-[(PPh 3 ) 2 PtNH=C(Ph) {cyt(− 2H)}]NO 3 and cis-[(PPh 3 ) 2 PtNH=C(Ph){ado(− 2H)}]NO 3 , quantitatively formed when the condensation reaction between the nucleoside and cis-[(PPh 3 ) 2 Pt(μ-OH)] 2 (NO 3 ) 2 is carried out in benzonitrile, prompted us to include, in this biological investigation, some of the related amidine nucleobase adducts, previously described.
Experimental section

General methods
Adenosine, cytidine and all the solvents (MeOH, Et 2 O, PhCN, CH 3 [20] , cis-[(PMe 3 ) 2 Pt(μ-OH)] 2 (NO 3 ) 2 [22] , cis-[(PPh 3 ) 2 PtHN=C(Me){1-MeCy(−2H)}]NO 3 (7a) [20] , cis-[(PPh 3 ) 2 PtHN=C(Ph){1-MeCy(−2H)}]NO 3 (7b) [21] , cis-[(PPh 3 ) 2 PtHN=C(Me) {9-MeAd(−2H)}]NO 3 (8a) [20] , cis-[(PPh 3 ) 2 PtHN=C(Me){9-MeAd (−2H)}]NO 3 (8b) [21] were synthesized as previously reported.
NMR with a Bruker 400 AMX-WB spectrometer (operating at 40.6 MHz). The 1 H chemical shifts were referenced to the residual impurity of the solvent and to TMS (tetramethylsilane). The external references were H 3 PO 4 (85% w/w in D 2 O) for 31 P and CH 3 NO 2 (in CDCl 3 at 50% w/w) for 15 N. Inverse detected spectra were obtained through heteronuclear multiple bond correlation (HMBC) experiments, using parameters similar to those previously reported [23] . ESI-MS (electrospray ionization mass spectrometry) spectra were performed with a MSD SL trap mass spectrometer (Agilent Technologies, Palo Alto, CA, USA) operating in positive ion mode from m/z 100 to 2200. A 5 × 10 − 6 M solution was directly infused into the ion source at a flow rate of 10 μL min −1 by a syringe pump. . In order to analyze the cytotoxic properties of 1, the compound has been obtained with an analogous procedure in water, heating the sample at 40°C for two weeks. 
Experiments with human cell lines
Pt(II) nucleosides (1-4) as well as the corresponding Pt(II) amidine nucleoside (5b, 6b) and nucleobase (7a, 7b, 8a, and 8b) derivatives were dissolved in DMSO just before the experiment and a calculated amount of drug solution was added to the growth medium. The final solvent concentration was 0.5%, which had no discernible effect on cell killing. Cisplatin was dissolved in purified water just before the experiment. MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and cisplatin were obtained from Sigma Chemical Co, St.Louis, USA.
Cell cultures
Human breast (MCF-7) carcinoma cell line along with melanoma (A375) cell line were obtained by American Type Culture Collection (ATCC, Rockville, MD). 2008 and its cisplatin resistant variant, C13*, are human ovarian cancer cell lines, and they were kindly provided by Prof. G. Marverti (Dept. of Biomedical Science of Modena University, Italy). A431 and A431/Pt are sensitive and resistant human cervical carcinoma cells, respectively; kindly provided by Prof. F. Zunino (Division of Experimental Oncology B, Istituto Nazionale dei Tumori, Milan, Italy). LoVo human colon-carcinoma cell line and its derivative multidrugresistant sub-line (LoVo MDR) were kindly provided by Prof. F. Majone (Dept. of Biology of Padova University, Italy). Cell lines were maintained in the logarithmic phase at 37°C in a 5% carbon dioxide atmosphere using the following culture media containing 10% fetal calf serum (Euroclone, Milan, Italy), antibiotics (50 units·mL iii) d-MEM "Dulbecco's modified eagle's medium" (Euroclone) for A375 cells.
Cytotoxicity assays
MTT test. The growth inhibitory effect towards tumor cell lines was evaluated by means of MTT (tetrazolium salt reduction) assay [24, 25] . Briefly, 3-8 · 10 3 cells/well, dependent upon the growth characteristics of the cell line, were seeded in 96-well microplates in growth medium (100 μL) and then incubated at 37°C in a 5% carbon dioxide atmosphere. After 24 h, the medium was removed and replaced with a fresh one containing the compound to be studied at the appropriate concentration. Triplicate cultures were established for each treatment. After 72 h, each well was treated with 10 μL of a 5 mg·mL −1 MTT saline solution, and following 5 h of incubation, 100 μL of an SDS solution in HCl 0.01 M was added. After overnight incubation, the inhibition of cell growth induced by the tested complexes was detected by measuring the absorbance of each well at 570 nm using a Bio-Rad 680 microplate reader. Mean absorbance for each drug dose was expressed as a percentage of the control untreated well absorbance and plotted vs. drug concentration. IC 50 values represent the drug concentrations that reduced the mean absorbance at 570 nm to 50% of those in the untreated control wells. Table 1 , are very similar to those of the nucleobase analogous, structurally characterized [18] . The presence of two sets of signals for the nucleoside is in line with the existence of two conformers resulting in the relative orientation, syn and anti, of the ribose groups with respect to the pyrimidinic ring. whereas the binding mode of the nucleoside was established by 15 Fig. 2 , the first resonance correlates with the adenine H8 proton at δ 5.83 and both of them show correlation with the N(6)H proton at δ 4.64 (partially overlapped with the ribose H2′ multiplet, at 300 MHz). These results led to the conclusion that the nucleoside is chelated to the metal through the N6 and N7 atoms, as previously found for the nucleobase 9-methyadenine [26] . Selected Table 1 . It is noteworthy that the replacement of the methyl group with the ribose does not change significantly the spectroscopic parameters of these nucleobase/nucleoside adducts.
Results and discussion
Syntheses of the nucleoside complexes
As [27] . For this last adduct the N1,N6-coordination of the nucleobase was confirmed by X-ray analysis [27] . The dinuclear species for 3 is characterized by the presence of two AB multiplets in the 31 P NMR spectrum, as well as of distinct resonances for the nucleobase H2, H8 and N(6)H protons (see Table 1 ), in line with the existence of two conformers resulting in the relative orientation, syn and anti, of the ribose groups with respect to the coordination plane of the metal. The reaction, monitored via 31 P NMR spectroscopy, in DMSO, leads initially to a mixture of products that slowly rearranges quantitatively into the thermodynamically stable species 3. As an example, the 31 P NMR spectrum of the mixture containing cis-[(PMe 3 ) 2 Pt(μ-OH)] 2 (NO 3 ) 2 and ado (molar ratio 1:2) in DMSO-d 6 is shown in Fig. 3 .
The spectrum obtained immediately after the dissolution of the reagents shows still a small amount of the reacting hydroxo complex (singlet at δ −23.9 ppm), in agreement with a relatively slow condensation reaction at ambient conditions. The main product (Fig. 3a) is characterized by an AB multiplet at δ −26.64 ( . In a few days at 27°C, these signals are completely replaced by two AB multiplets, having relative intensities ca. 45:55, at higher field (Fig. 3b) , attributable to the isolated dinuclear species 3. The spectrum does not change after 4 days at 75°C, suggesting a high stability of the dimeric structure of this adduct.
Syntheses of the amidine complexes
When the reaction of cis-[(PPh 3 ) 2 Pt(μ-OH)] 2 (NO 3 ) 2 with the nucleosides cyt and ado is carried out in solution of nitriles (RCN, R= Me, Ph) the amidine derivatives cis-[(PPh 3 ) 2 PtNH=C(R){cyt(− 2H)}]NO 3 (R= Me, 5a; R=Ph, 5b) and cis-[(PPh 3 ) 2 PtNH=C(R){ado(−2H)}]NO 3 (R= Me, 6a: R=Ph, 6b), depicted in Scheme 3, are formed.
The formal insertion of a nitrile molecule into a Pt-nitrogen bond of the cytidine that occurs at room temperature in a few hours, is quantitative (by 31 P NMR) and no intermediates are detectable. On the contrary, in the case of adenosine the initial product is the nucleoside adduct 4, which slowly reacts with the solvent to give the amidines 6a,b.
The products have been isolated, in good yield, as pale yellow solids and characterized by elemental analysis and NMR spectroscopy in CDCl 3 . The 1 H and 31 P NMR data are very similar to those exhibited by the nucleobase analogs [20, 21] , cis-[(PPh 3 ) 2 PtNH=C(R){1-MeCy (−2H)}]NO 3 (R = Me, 7a: R = Ph, 7b), cis-[(PPh 3 ) 2 PtNH=C(R){9-MeAd(−2H)}]NO 3 (R = Me, 8a: R = Ph, 8b) previously characterized. In Table 2 H spectra, suggesting a preferred orientation of the ribose group with respect to the nucleobase ring (single conformation) or a fast rotation around the glycosidic bond.
In solution, complexes 5a and 6a are indefinitely stable only in CH 3 CN. In chlorinated solvents (or DMSO) 5a slowly releases CH 3 CN and forms reversibly a complex mixture of uncharacterized products while 6a forms 4.
The analogous complexes with benzonitrile are stable in PhCN as well as in solution of DMSO or chlorinated solvents.
Cytotoxicity tests
Pt(II) nucleosides (1-4) as well as the corresponding Pt(II) benzamidine nucleosides (5b, 6b) and acetamidine (7a, 8a) or benzamidamide (7b, 8b) nucleobase derivatives were evaluated for their cytotoxic activity towards a panel of 8 human tumor cell lines including examples of ovarian (2008 and C13*), cervical (A431 and A4317Pt), colon (LoVo and LoVo MDR) and breast (MCF-7) cancer and melanoma (A375). Acetamidine Pt(II) nucleosides (5a, 6a) were not tested for their cytotoxicity owing to their poor stability in DMSO. Cytotoxicity was evaluated by means of MTT tests after 72 h of treatment with increasing concentrations of the tested compounds. For comparison purposes, the cytotoxicity of cisplatin, the most widely used anticancer metallodrug, was evaluated in the same experimental conditions. IC 50 values, calculated from dose-survival curves, are shown in Table 3 .
Pt(II) nucleosides (1-4) proved to be completely ineffective over 8 cell lines; the negligible activity shown by 1-4 could be associated with the high kinetic inertness of these molecules as assessed by mass and NMR studies. Among Pt(II) amidine nucleoside and nucleobase complexes, cytosine derivatives proved to be much more effective than those containing adenine. In particular, adenosine and adenine derivatives 6b, 8a and 8b showed mean IC 50 (μM) values of 24.87 (34.24-12.41), 21.68 (24.91-16.34 ) and 20.55 (24.73-10.47), respectively, which were about four times higher than that of cisplatin (5.45 μM). Among Pt(II) cytidine and cytosine complexes, acetamidine nucleobase 7a showed the worst cytotoxic potency, eliciting a cancer cell growth inhibition roughly 2.5 times lower than cisplatin. Conversely, Pt(II) benzamidine nucleobase 7b distinguished itself as the most promising derivative, being able to decrease cell viability about 2 times more effectively than cisplatin (average IC 50 of 3.22 μM and 5.45 μM for 7b and cisplatin, respectively). Pt(II) benzamidine nucleoside 5b, despite retaining an antiproliferative activity slightly lower than that of the relative Pt(II) nucleobase complexes 7a and 7b (average IC 50 of 3.22 and 6.01 μM for 7b and 7a, respectively), has been found to possess a cytotoxic potency quite similar to that of the reference metallodrug. Among nucleobase amidine Pt(II) complexes, benzamidine derivatives proved to be more effective with respect to acetamidine analogs. This behavior may be related to the more lipophilic properties of the phenyl ring that could favor the crossing of the cell membrane. These data are in line with the results previously reported concerning trans-Pt(II) amidine complexes [28, 29] .
The in-house panel also included two cell lines that have been selected for their resistance to cisplatin (human ovarian adenocarcinoma C13* cells, human cervical carcinoma A431/Pt cells). Although cisplatin resistance is multifactorial, the main molecular mechanisms involved in Pt resistance of C13* and A431/Pt have been identified. In particular, in C13* cells' resistance is correlated to reduced cellular drug uptake, high cellular glutathione and thioredoxin reductase levels and enhanced repair of DNA damage [30, 31] . In A431/Pt cells, resistance is due to a defect in drug uptake and to decreased levels of proteins involved in DNA mismatch repair (MSH2), which causes an increased tolerance to cisplatin-induced DNA damage [32] . By comparing the RF values (where RF is the resistance factor and is defined as the ratio between IC 50 values calculated for the resistant cells and those arising from the sensitive ones), new Pt(II) amidine nucleoside and nucleobase complexes were found to be able to overcome cisplatin resistance. The resistance factors calculated for these derivatives were about 8 and 3 times lower than that of cisplatin on the 2008-C13* and A431-A431/Pt cell pairs, respectively.
Additionally, Pt(II) amidine complexes were tested against a multidrug resistant (MDR) colon carcinoma subline, LoVo MDR cells. It is well known that acquired MDR, whereby cells become refractory to multiple drugs, poses a most important challenge to the success of anticancer chemotherapy. The resistance of LoVo MDR cells to doxorubicin, a drug belonging to the MDR spectrum, is associated with an overexpression of the multi-specific drug transporters, such as, for example, the 170 kDa P-glycoprotein (P-gp) [33] . Although cisplatin is not a P-glycoprotein substrate; many multidrug resistance protein (MRP1, MRP2, MRP4) have been found involved in platinum complex transport and are responsible for its efflux/afflux from the cell [34] [35] [36] . Cytotoxicity assays testing Pt(II) amidine derivatives against this cell line pair showed a similar pattern of response across the parental and the resistant subline thus suggesting that these new Pt(II) complexes are not potential MDR substrates.
Conclusions
The main results of this study can be summarized as follows: a) the substitution of the methyl group in the model nucleobase 1-MeCy and 9-MeAd with the ribose group does not change significantly the reactivity pattern of these biomolecules toward the hydroxo complex cis-[L 2 Pt(μ-OH)] 2
2+
. The less hindered phosphines stabilize polynuclear adducts in which the deprotonated nucleoside acts as bridging ligand. The di-and/or trimerization of the nucleoside adducts is prevented when the hydroxo reagent is stabilized by PPh 3 . b) A similar effect of the phosphine ligands is observed in the activation of nitriles: the insertion of a molecule of CH 3 CN or PhCN occurs only with the less basic PPh 3 . c) Among the isolated complexes, only the amidine derivatives exhibit a clear cytotoxic activity toward different human tumor cell lines. In particular, the benzamidine cis-[(PPh 3 ) 2-PtHN=C(Ph){1-MeCy(−2H)}]NO 3 (7b) shows interesting properties, in terms of antiproliferative effects, even toward C13* cisplatin resistant cells and this important finding could be due to a different mechanism of action with respect to the reference metallodrug. 
